Roivant Sciences Ltd. (ROIV) Research

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.

Market snapshot

Symbol
ROIV
Price
$31.43
Day change
+0.74%
Market cap
$22.6B
P/E ratio
-73.62x
52-week range
10.705-32.793
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$37.17

Peer companies

  • Ascendis Pharma A/S (ASND)
  • BridgeBio Pharma, Inc. (BBIO)
  • Exact Sciences Corporation (EXAS)
  • Ionis Pharmaceuticals, Inc. (IONS)
  • Jazz Pharmaceuticals plc (JAZZ)
  • Moderna, Inc. (MRNA)
  • Atrium Therapeutics, Inc. (RNA)
  • Royalty Pharma plc (RPRX)

Recent insider activity

  • Venker Eric — M-Exempt (200000 shares) on 2026-05-22
  • Venker Eric — M-Exempt (200000 shares) on 2026-05-22
  • Venker Eric — S-Sale (200000 shares) on 2026-05-22
  • Venker Eric — F-InKind (34483 shares) on 2026-05-20
  • Pulik Richard — F-InKind (18962 shares) on 2026-05-20

Open Roivant Sciences Ltd. (ROIV) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.